Navigation Links
Lupus more severe in patients with Southern European ancestry
Date:6/11/2008

Paris, France, Wednesday 11 June 2008: Systemic lupus erythematosus (SLE) patients with a higher percentage of ancestry from southern Europe have more severe disease manifestations, according to new research presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.

According to the results of the research, northern European ancestry is shown to be associated with the relatively milder mucocutaneous (skin) manifestations of SLE, whereas southern European ancestry contributes to more severe manifestations of the disorder such as nephritis (inflammation of the kidneys) and increased production of specific autoantibodies (antibodies that fail to recognise and therefore attack the body's own cells, tissues or organs).

SLE is a complex autoimmune disease characterised by chronic inflammation and damage to body tissues, which occurs as a result of the production of abnormal antibodies that target and cause damage to cells of the patient's body, including immune cells. SLE has the potential to affect a variety of areas of the body, including the heart, lungs, kidneys, joints, and/or nervous system. The course of the disease is unpredictable, with periods of illness (called flares) alternating with remission. Lupus can occur at any age but is most common in women, particularly of non-European descent. Until now, the relationship between specific European ancestry and SLE severity has not been studied.

Professor Lindsey A Criswell of the University of California, San Francisco, USA, who led the study, said: "Exploring the ancestry and genetic make-up of patients in relation to their disease today helps us to better understand the complex nature of SLE and why it manifests itself differently in different people. This study shows a clear correlation between specific European ancestry and SLE disease severity and autoantibody production, which may further assist in understanding the ris
'/>"/>

Contact: Rory Berrie / Camilla Dormer
eularpressoffice@uk.cohnwolfe.com
44-077-892-70392
European League Against Rheumatism
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Blood Cancer Drug Shows Promise Against Lupus
2. Annie and Toms Race to the Altar Inspires Lupus Community
3. Lupus Live Web Chat Focuses on Medication Management
4. Lupus Community Rallies Behind Fiancee With Lupus in Race to the Altar
5. Abnormal editing of gene messages may be a cause of lupus
6. Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala
7. 5th Annual World Lupus Day Philadelphians Take Part In a Global Rally of Support
8. Grammy Award Winner Patti LaBelle Is Featured Entertainer at Lupus Foundation of America Awards Gala
9. Lupus Organizations Issue International Call-to-Action to Combat Disease Affecting Five Million People
10. Lupus Foundation of America Seeks Funding Proposals for Research Studies on Childhood Lupus, Nervous System Involvement, and More
11. The Alliance for Lupus Research Announces 2008 Grantees
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Within3 Expands into Mobile Applications 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 1Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 2Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 3Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 4Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 5Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 6URI research couples method targets cancerous tumors 60165 1URI research couples method targets cancerous tumors 60165 2URI research couples method targets cancerous tumors 60165 3URI research couples method targets cancerous tumors 60165 4Scientists are first to observe the global motions of an enzyme copying DNA 10548 1Scientists are first to observe the global motions of an enzyme copying DNA 10548 2Scientists are first to observe the global motions of an enzyme copying DNA 10548 3Scientists are first to observe the global motions of an enzyme copying DNA 10548 4